Effect of prenatal EPA and DHA on maternal and umbilical cord blood cytokines

Ellen L. Mozurkewich1*, Deborah R. Berman2, Anjel Vahratian2, Chelsea M. Clinton3, Vivian C. Romero4, Julie L. Chilimigras1, Delia Vazquez5, Clifford Qualls6 and Zora Djuric7

Abstract

Background: Investigators have hypothesized that omega-3 fatty acid supplementation may modulate the immune response. However, available evidence is conflicting. We performed this study to investigate the effect of prenatal eicosapentaenoic acid (EPA)- and docosahexaenoic acid (DHA)-rich fish oil supplementation on maternal and fetal cytokine production.

Methods: This study is a secondary analysis of a randomized controlled trial designed to assess whether prenatal EPA- or DHA-rich fish oil supplementation would prevent perinatal depressive symptoms among women at risk. Enrolled participants received EPA-rich fish oil (1060 mg EPA plus 274 mg DHA), DHA-rich fish oil (900 mg DHA plus 180 mg EPA) or soy oil placebo. Maternal venous blood was collected at enrollment (12–20 weeks gestation) and after supplementation (34–36 weeks gestation). Umbilical cord blood was collected at delivery. We analyzed stored plasma specimens for 16 human cytokines using multiplex immunoassays. Maternal and cord blood cytokine levels were compared among the treatment groups. Associations of serum DHA and EPA with maternal and cord blood cytokines were explored via regression analysis.

Results: We enrolled 126 women, of whom 118 completed the trial. Prenatal supplementation with EPA-rich fish oil significantly lowered maternal IL6, IL15, and TNFα concentrations. However, supplementation with DHA-rich fish oil had no significant effect on maternal cytokine profiles. Maternal serum DHA fraction was significantly associated with IL1α, and maternal serum DHA and EPA fractions were significantly associated with IL 10 concentrations after supplementation. Compared with placebo, supplementation with EPA- or DHA-rich fish oils had no significant effect on cord blood cytokine concentrations.

Conclusions: Prenatal supplementation with EPA-rich fish oil significantly reduced levels of several inflammatory cytokines in maternal plasma, while prenatal DHA-rich fish oil had no significant effect on cytokine concentrations. Supplementation with EPA- and DHA- rich fish oil had no significant effect on umbilical cord blood cytokine concentrations.

Keywords: Cytokines, EPA, DHA, Umbilical cord blood

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Inflammation has been associated with many complications of pregnancy, including perinatal depression, gestational diabetes, preterm delivery and preeclampsia [1, 2]. For example, a recent case-control study found that elevated concentrations of TNF-α in mid-pregnancy were significantly associated with diagnoses of preeclampsia later in pregnancy, [3] Similarly increases in circulating IL-1β, IL-6, IL-18 and TNF have been demonstrated in women with GDM complicating pregnancy compared with controls [2]. Likewise, a recent case-control study of inflammatory markers among subjects with perinatal depression found that a diagnosis of major depressive disorder was significantly related to increased concentrations of TNFα [4].

The Western diet has been postulated to be one important cause of inflammation [5, 6]. Some investigators have related the increase in inflammatory disorders in the developed world to an imbalance in dietary intake in omega-6 to omega-3 fat compared to historical human diet [7]. Dietary supplementation with omega-3 fatty acids has therefore been proposed as a mechanism to potentially reduce inflammation [7].

Omega-3 fatty acids, both in food and through supplementation with fish or algal oil, have long been believed to limit or modulate the inflammatory response through modulation of cytokine production. Two early omega-3 fatty acid supplementation studies in healthy adults using greater than 2.4 g of EPA plus DHA daily reported significantly reduced blood cytokines TNFα, IL1β, and IL6 [7–9]. However, a systematic review of randomized trials using DHA and EPA supplementation among healthy adults found no consistent effect of supplementation on blood cytokines [10]. The majority of studies investigating the effect of dietary supplementation on cytokines have measured cytokines after endotoxin stimulation of cells, whereas, more recent studies have measured circulating soluble cytokines using multiplex immunoassays [11]. It is not known whether fish oil supplementation during pregnancy modulates maternal cytokine production or whether supplementation alters cytokine concentrations in the umbilical cord blood.

This study is a secondary analysis of a double-blind randomized control trial carried out to test the hypothesis that EPA- or DHA-rich fish oil supplementation would reduce perinatal depressive symptoms. A secondary aim of the study was to determine the effect of prenatal EPA- and DHA- risk fish oil supplementation on maternal cytokine profiles as well as on cytokines in umbilical cord blood [12]. We hypothesized that prenatal EPA- and DHA-rich fish oil supplementation would reduce concentrations of the major pro-inflammatory cytokines IL-β, IL-6, and TNF-α in both maternal and umbilical cord plasma.

Methods
This study is a planned secondary analysis of plasma samples that were collected as part of a prospective, double-blind randomized controlled trial of fish oil supplementation for prevention of depressive symptoms among pregnant women [12, 13]. To be eligible to participate in the parent study, women had to be between 12 and 20 weeks gestation in a singleton pregnancy and to be at risk for depression based on an Edinburgh Postnatal Scale Score between 9 and 19 or a past history of depression. Potential subjects consuming more than two fish meals per week were not eligible to participate. Subjects were recruited from the antenatal clinics of the University of Michigan Medical Center (Ann Arbor, MI) and St. Joseph Mercy Health System (Ypsilanti, MI). The overall details of the trial design have been previously reported [12, 13].

The sample size for the study was determined based on the expected Beck Depression Inventory scores among women at risk for depression. The parent study was designed to detect a 50% reduction in the primary outcome for the trial, the Beck Depression Inventory score at 6 weeks postpartum [12, 13]. Maternal and umbilical cord cytokine levels were a pre-specified secondary outcome of the study [12]. We used a random number table maintained in the University of Michigan Investigational Drug Pharmacy for random allocation. Full details of the randomized, double-blinded study design as well as the primary and clinical outcomes have been previously reported [12, 13].

There were 126 subjects enrolled in the parent study between October 2008 and May 2011. They were randomly assigned to receive EPA rich fish oil (1060 mg EPA plus 274 mg DHA), DHA rich fish oil (900 mg DHA plus 180 mg EPA), or soy oil placebo and were followed longitudinally through pregnancy from their enrollment at 12–20 weeks’ gestation until 6 weeks postpartum. Maternal blood was drawn at enrollment and again at 34–36 weeks gestation. The minimum supplementation time was 14 weeks. Because of the double-dummy design of the trial, all subjects received some placebo capsules. Umbilical cord blood was obtained at delivery.

During the course of the study, eight subjects dropped out and 118 subjects completed the study. There were 126 maternal samples available for cytokine analysis at enrollment and 113 maternal samples available for analysis after supplementation (34–36 weeks). There were 102 cord blood samples available for analysis of cytokine profiles. The flow diagram of participant enrollment and sample availability is depicted Fig. 1.

Sample collection and biochemical assessment
We obtained venous blood after a four hour fast. Fetal cord blood was collected at delivery. Cord blood was obtained after severance of the umbilical cord by passive flow of
mixed arterial and venous blood into EDTA-containing tubes. All blood samples were processed by centrifugation within 12 h of collection and the resultant plasma was stored at −80 °C [12, 13]. Multiplex immunoassays for cytokines IL-1α, IL-1β, IL-2, IL-4,IL-5,IL-6,IL-8, IL-10, IL-12p70, IL-13, IL-15, IL-17, IFNγ,MCP-1, TNFα, and TNFβ were performed on plasma samples using the Q-Plex™ Human Cytokine - Screen IR (16-plex), a fully quantitative ELISA-based Infrared (IR) assay system (Quansys Biosciences, Logan, UT).

Serum EPA and DHA, had been previously assayed from sample collection of maternal and cord blood into red top non-additive tubes at the same time points, with DHA and EPA being evaluated as a measure of compliance [13]. As we have previously reported, supplementation with the DHA-rich fish oil significantly increased serum DHA levels in maternal and cord blood. Similarly, supplementation with EPA-rich fish oil significantly increased maternal serum EPA fraction but not cord blood EPA. These variables were available from prior study to evaluate as predictors of maternal and cord blood plasma cytokine levels [13].

**Ethics**

The procedures followed were approved and conducted in accordance with the institutional review boards of the University of Michigan Medical Center, Ann Arbor, MI, St. Joseph Mercy Hospital in Ypsilanti, MI, and The University of New Mexico Health Sciences Center Human Research Protections Office. All subjects gave written informed consent to participate in the study. The trial was registered on 7/7/2008 at clinicaltrials.gov: NCT00711971 under the title: “Does Fish Oil Prevent Depression in Pregnancy and Postpartum”.

**Statistics**

For a simple post-hoc power analysis, we used our change in maternal plasma IL-6 at visit 3 (34–36 weeks) between EPA-rich fish oil and placebo. For our sample size of 37 in the EPA group and 40 in the placebo group, we could detect a group difference in the change in IL-6 of 80 pg/ml with 80% power and a significance of 0.05. This power analysis was based on the standard deviations (94 pg/ml and 176 pg/ml) that we observed in these two groups. Although this study's sample size was
determined in order to evaluate a different primary outcome measure (the Beck Depression Inventory score at 6 weeks’ postpartum), it had adequate power (80%) to detect a group difference between the change in maternal IL-6 after supplementation compared to placebo.

We computed median and interquartile range values for the all of the cytokines at each of the time points. If the value for a sample was reported as “below detectable limits”, the value of half the lower limit of detection for the cytokine was used for the purposes of subsequent comparisons, a technique known as “single value imputation” [14]. Cytokine concentrations were log-transformed in order to symmetrize the skewed distributions. All analyses were according to intention to treat principles. For all ANCOVA analyses that evaluated the effect of DHA- and EPA-rich fish oil supplementation on maternal cytokines, we adjusted for the baseline values of fatty acids (EPA and DHA fractions) and cytokines by subtraction of visit 1 values from visit 3 values. Where there was a significant treatment effect, post hoc multiple comparisons between the treatments was done by Fisher’s Least Significant Difference method.

In addition, we adjusted for maternal BMI at enrollment (visit 1). Because of the potential correlation of allocated treatment group with EPA and DHA concentrations, the model was analyzed with and without each of these variables. Pearson’s correlation coefficients were computed to describe the relationship between serum EPA and DHA fractions, maternal BMI and the cytokines under study.

We performed ANCOVA analyses to describe the relationship between the group of allocation and cytokines in the umbilical cord blood. All analyses were adjusted for exposure to labor (regardless of mode of delivery), gestational age at delivery, birth weight, as well as DHA and EPA concentrations in umbilical cord blood. Analyses were carried out with all variables in the model as well as with correlated variables removed. Pearson correlation coefficients were constructed to evaluate the relationship between each of the variables in the model and the cytokines under study in order to assess the changes in cytokines between enrollment and late pregnancy pooled across groups, we computed the differences between visits 3 and visit 1 and compared to no change using one sample t tests.

Results
Effect of fish oil supplementation on maternal cytokines
There were 126 samples available for maternal cytokine analyses at enrollment and 113 samples available after supplementation. The median and interquartile ranges of the maternal cytokines at two time points are presented in Table 1.

There was no statistically significant change in the concentrations of the cytokines under study between early and late pregnancy. We modeled the change in the cytokines of interest between enrollment (12–20 weeks) and after supplementation (34–36 weeks) with adjustment for body mass index (BMI) at enrollment, DHA, EPA, and group allocation. EPA-rich fish oil treatment decreased plasma concentrations of IL6 (P = 0.02), IL 15 (P = 0.03), and TNF α (P = 0.03) after adjustment for baseline cytokine concentrations, and BMI. Treatment group was not significantly related to the change in IL 1 β, IL2, IL5, IL8, IL12P70, IL17, IFN γ, or MCP1 on post hoc multiple comparisons. We found no significant effect of the DHA-rich fish oil treatment on cytokine concentrations, when compared with placebo.

Our model evaluated the relationship of the variables in the model with the cytokines of interest. We found a positive association between maternal serum DHA fraction, adjusted for DHA fraction at baseline, with IL 1 α (P = 0.05) and with IL10, a cytokine with both pro- and anti-inflammatory properties (P = 0.05) [15]. By contrast EPA fraction was inversely (negatively) associated with IL10 concentrations (P = 0.04). BMI at entry to the study was inversely associated with TNF beta (P = 0.04). These relationships are summarized in Table 2. These findings were not altered when the correlated variable of study group allocation as well as EPA and DHA fraction were analyzed separately in the model.

For fetal (cord blood) cytokines, there were 102 cord blood samples available for analysis. The median and interquartile ranges of the cord blood cytokines are represented in Table 3. There were no significant differences in cord blood cytokines according to treatment group. Cord blood DHA fraction was negatively correlated with cord blood IL 1 β (P = 0.03), a relationship that however did not persist after adjusting for labor and gestational age at delivery. There were no other significant associations between EPA or DHA to concentrations of any of the cytokines that we studied. Of other variables included in the model, we found that gestational age was positively correlated with IL8 (P = 0.05). When serum EPA and DHA fraction were excluded from the model, exposure to labor was positively correlated with IL10 (P = 0.04). There were no other significant relationships demonstrated.

Discussion
We found that some maternal plasma cytokine concentrations may be significantly modulated by dietary supplementation during pregnancy. Our study found that supplementation with EPA-rich fish oil in particular resulted in reduced concentrations of IL6 and TNFα, inflammatory cytokines that have been associated with major depression in other studies [16]. These findings are similar to the results of a randomized control trial of supplementation with 2 g/day of omega-3 fatty acids.
**Table 1** Maternal cytokine values before and after supplementation

| Cytokine | LLD Enrollment 1 (N = 126) median (IQR) | Post-supplementation (N = 113) median (IQR) |
|----------|------------------------------------------|-------------------------------------------|
| IL1α     | 6.66 (6.66,6.66)                         | 6.66 (6.66,6.66)                          |
|          | EPA                                      | EPA                                       |
|          | DHA                                      | DHA                                       |
|          | Placebo                                  | Placebo                                  |
| IL1β     | 7.806 (7.81,7.81)                        | 7.81 (7.81,15.4)                         |
|          | EPA                                      | EPA                                       |
|          | DHA                                      | DHA                                       |
|          | Placebo                                  | Placebo                                  |
| IL2      | 2.584 (2.58,2.58)                        | 2.58 (2.58,61.8)                         |
|          | EPA                                      | EPA                                       |
|          | DHA                                      | DHA                                       |
|          | Placebo                                  | Placebo                                  |
| IL4      | 0.776 (0.78,0.78)                        | 0.78 (0.78,7.81)                         |
|          | EPA                                      | EPA                                       |
|          | DHA                                      | DHA                                       |
|          | Placebo                                  | Placebo                                  |
| IL5      | 35.05 (35.1,35.1)                        | 35.1 (35.1,35.1)                         |
|          | EPA                                      | EPA                                       |
|          | DHA                                      | DHA                                       |
|          | Placebo                                  | Placebo                                  |
| IL6      | 18.466 (18.6,18.6)                       | 18.5 (18.5,18.5)                         |
|          | EPA                                      | EPA                                       |
|          | DHA                                      | DHA                                       |
|          | Placebo                                  | Placebo                                  |
| IL8      | 9.894 (9.9,9.9)                          | 9.9 (9.9,9.9)                            |
|          | EPA                                      | EPA                                       |
|          | DHA                                      | DHA                                       |
|          | Placebo                                  | Placebo                                  |
| IL10     | 2.94 (2.94,2.94)                         | 2.94 (2.94,2.94)                         |
|          | EPA                                      | EPA                                       |
|          | DHA                                      | DHA                                       |
|          | Placebo                                  | Placebo                                  |
| IL12p70  | 45.458 (45.5,45.5)                       | 45.5 (45.5,45.5)                         |
|          | EPA                                      | EPA                                       |
|          | DHA                                      | DHA                                       |
|          | Placebo                                  | Placebo                                  |
| IL13     | 12.608 (12.7,12.7)                       | 12.6 (12.6,12.6)                         |
|          | EPA                                      | EPA                                       |
|          | DHA                                      | DHA                                       |
|          | Placebo                                  | Placebo                                  |
| IL15     | 7.734 (7.7,7.7)                          | 7.7 (7.7,7.7)                            |
|          | EPA                                      | EPA                                       |
|          | DHA                                      | DHA                                       |
|          | Placebo                                  | Placebo                                  |
| IL17     | 45.586 (45.6,45.6)                       | 45.6 (45.6,45.6)                         |
|          | EPA                                      | EPA                                       |
|          | DHA                                      | DHA                                       |
|          | Placebo                                  | Placebo                                  |
| IFNγ     | 58.506 (58.5,58.5)                       | 58.5 (58.5,58.5)                         |
|          | EPA                                      | EPA                                       |
|          | DHA                                      | DHA                                       |
|          | Placebo                                  | Placebo                                  |
| MPC1     | 6.686 (6.7,6.7)                          | 6.7 (6.7,7.5)                            |
|          | EPA                                      | EPA                                       |
|          | DHA                                      | DHA                                       |
|          | Placebo                                  | Placebo                                  |
| TNFa     | 15.146 (15.1,15.1)                       | 15.1 (15.1,15.1)                         |
|          | EPA                                      | EPA                                       |
|          | DHA                                      | DHA                                       |
|          | Placebo                                  | Placebo                                  |
among obese pregnant women. In that trial, prenatal supplementation was found to reduce inflammatory markers in maternal adipose tissue and in the placenta [17]. This finding is in contrast with previous observations among healthy non-pregnant adults in which supplementation with fish oil up to 3.5 g/day had no significant effect on cytokine profiles [10]. The reason for this finding is unknown, but may relate to the unique maternal immunology during pregnancy. Our findings were consistent with previous reports which suggest that EPA may be more effective than DHA in reducing inflammatory biomarkers [18].

By contrast, we found that fish oil supplementation in doses of approximately 1 g/day had no significant effect on umbilical cord blood cytokine concentrations. Our findings are not consistent with a systematic review of prior prenatal supplementation trials that found significant reduction of IL13 in infants of mothers who took prenatal fish oil supplementation [19]. This finding is also in contrast to our previously reported secondary analysis of the effect of fish oil supplementation on chemokine profiles among participants in this trial. That analysis found that the EPA- and DHA-rich fish oil had no significant effect on maternal chemokine concentrations, but significantly influenced cord blood chemokine ratios [20]. The reason for this discrepancy is unknown but may be related to the number of cord blood samples with cytokine concentrations that fell below detectable limits.

Based on our findings, we conclude that the fatty acid content of the prenatal maternal diet may modulate the maternal immune response, although prenatal supplementation did not significantly affect cord blood cytokine profiles in our study.

Strengths of our study included blinded assessment of outcomes, randomized design, and intent-to-treat analyses. The study also had several limitations. These included the differing times of day at which maternal blood samples were procured, a result of study procedures being timed with clinical care. However, all maternal samples were drawn after a four hour fast with only low-fat meals allowed on the day of the blood draw.

Another limitation of our study is that many cytokine concentrations were below the limits of detection for the assay used. These results were consistent with the results from other studies analyzed in the same laboratory and all of the study samples were analyzed on the same date. Likewise, the sample size of our study was based on the primary outcome of the Beck Depression Inventory score at 6 weeks’ postpartum. Nevertheless, our post-hoc power analysis suggests that this secondary study had reasonable

| Variable | Cytokine | Slope | Standard error +/- | Significance |
|----------|----------|-------|-------------------|-------------|
| EPA-rich fish oil group | IL6 | −76.3 | 32.2 | 0.02 |
| EPA-rich fish oil group | IL15 | −23.8 | 10.9 | 0.03 |
| EPA-rich fish oil group | TNFα | −141.1 | 62.6 | 0.03 |
| DHA fraction | IL1α | 4.64 | 2.33 | 0.05 |
| DHA fraction | IL10 | 4.82 | 2.36 | 0.04 |
| EPA fraction | IL10 | −18.8 | 8.42 | 0.03 |
| BMI at entry | TNFβ | −0.64 | 0.32 | 0.05 |

All analyses were adjusted for the following variables: Baseline concentrations of each cytokine, maternal BMI, maternal serum EPA fraction adjusted for baseline and DHA fraction adjusted for study baseline.

Table 1 Maternal cytokine values before and after supplementation (Continued)

| Cytokine | LLD Enrollment 1 N = 126 | Post-supplementation N = 113 |
|----------|--------------------------|-----------------------------|
|          | median | IQR | median | IQR |
| DHA      | 15.1   | (15.1,15.1) | 15.1   | (15.1,41.5) |
| Placebo  | 15.1   | (15.1,48.2) | 15.1   | (15.1,15.1) |
| TNFβ     | 4.956  |          | 4.96   | (4.96,4.96) |

All values in pg/ml
IQR = inter quartile range
LLD = lower limit of detection
Range of values below detectable limits from 2.5 to 83.3%
Numbers of samples per group:
EPA = 37
DHA = 36
Placebo = 40
power to detect a treatment effect of the fish oil supplementation on cytokine concentrations.

Additionally, our study was also limited by its double-dummy design which meant that all subjects in the intervention groups received soy oil placebo capsules along with the EPA- and DHA-rich fish oil capsules. Finally, it should be noted that the subjects were selected based on predisposition to depression and may have not been representative of the general population of pregnant women.

Conclusions
Our findings allow us to hypothesize that among women with perinatal depressive symptoms related to inflammation, prenatal EPA-rich fish oil supplementation may reduce plasma concentrations of inflammatory cytokines. Current research in depression is moving toward identification of a subset of depressed individuals in whom dysregulated cytokine production may play a role in pathogenesis. Future research should focus on the role of omega-3 fatty acids, in particular EPA, in modulation of the immune response in this population, and should work to elucidate the relationship of inflammatory cytokines with depressive symptomatology in these individuals.

Abbreviations
DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; IFNγ: Interferon γ; IL-1α: Interleukin 1α; IL-1β: Interleukin 1β; IL-2: Interleukin 2; IL-4: Interleukin 4; IL-5: Interleukin 5; IL-6: Interleukin 6; IL-8: Interleukin 8; MCP-1: Monocyte chemotactic protein; TH1: Type 1 T helper cells; TNFα: Tumor necrosis factor α; TNFβ: Tumor necrosis factor β

Acknowledgements
Dr. Daniel Remick’s laboratory at Boston University performed the assays that were described in this manuscript. Dr. Remick and Dr. Elizabeth Duffy assisted with assay selection and performance. Harold Nelson, MS, computed means, medians, standard deviations and interquartile ranges of the cytokines under study.

Funding
This project was supported by the NIH R21 AT004166-03S1 (NCCAM), as well as a University of Michigan Clinical Research Initiatives grant and the University of Michigan General Clinical Research Center (now the Michigan Clinical Research

### Table 3 Cord blood cytokine concentrations

|               | LLD | median       | IQR       |
|---------------|-----|--------------|-----------|
| IL-1α         | 6.664 | 6.66 (6.66,13.9) | 6.66 (6.66,13.1) |
| IL-1β         | 7.806 | 7.81 (7.81,60.1) | 7.81 (7.81,47.4) |
| IL-2          | 2.538 | 33.7 (2.58,17) | 33.7 (21.8,69.2) |
| IL-4          | 0.776 | 0.776 (0.785,2) | 0.776 (0.784,5) |
| IL-5          | 35.05 | 35.1 (35.11,14) | 35.1 (35.11,24) |
| IL-6          | 18.466 | 20.1 (18.5,65.1) | 20.1 (18.5,40.7) |
| IL-8          | 9.894 | 35.7 (9.89,83) | 9.895 (9.89,55.9) |
| IL-10         | 2.94 | 2.94 (2.94,17) | 2.94 (2.94,36.3) |
| IL-12p70      | 45.458 | 45.5 (45.51,98) | 45.5 (45.51,50) |
| IL-13         | 12.608 | 12.6 (12.6,67.3) | 12.6 (12.6,36.3) |
| IL-15         | 7.734 | 7.73 (7.73,73) | 7.73 (7.73,73) |
| IL-17         | 45.586 | 45.6 (45.6,26.2) | 45.6 (45.6,46.5) |
| IFNγ          | 58.506 | 58.5 (58.5188) | 58.5 (58.5193) |
| MCP-1         | 5.686 | 309 (192,509) | 309 (188,473) |
| TNFα          | 15.146 | 15.1 (15.1,101) | 15.1 (15.1,101) |

|               | LLD | median       | IQR       |
|---------------|-----|--------------|-----------|
| IL-1α         | 6.664 | 6.66 (6.66,13.9) | 6.66 (6.66,13.1) |
| IL-1β         | 7.806 | 7.81 (7.81,60.1) | 7.81 (7.81,47.4) |
| IL-2          | 2.538 | 33.7 (2.58,17) | 33.7 (21.8,69.2) |
| IL-4          | 0.776 | 0.776 (0.785,2) | 0.776 (0.784,5) |
| IL-5          | 35.05 | 35.1 (35.11,14) | 35.1 (35.11,24) |
| IL-6          | 18.466 | 20.1 (18.5,65.1) | 20.1 (18.5,40.7) |
| IL-8          | 9.894 | 35.7 (9.89,83) | 9.895 (9.89,55.9) |
| IL-10         | 2.94 | 2.94 (2.94,17) | 2.94 (2.94,36.3) |
| IL-12p70      | 45.458 | 45.5 (45.51,98) | 45.5 (45.51,50) |
| IL-13         | 12.608 | 12.6 (12.6,67.3) | 12.6 (12.6,36.3) |
| IL-15         | 7.734 | 7.73 (7.73,73) | 7.73 (7.73,73) |
| IL-17         | 45.586 | 45.6 (45.6,26.2) | 45.6 (45.6,46.5) |
| IFNγ          | 58.506 | 58.5 (58.5188) | 58.5 (58.5193) |
| MCP-1         | 5.686 | 309 (192,509) | 309 (188,473) |
| TNFα          | 15.146 | 15.1 (15.1,101) | 15.1 (15.1,101) |

All values in pg/ml
IQR = interquartile range
LLD = lower limit of detection
Range of values below detectable limits from 2.9 to 84.8%
Number of samples per group:
EPA = 35
DHA = 33
Placebo = 34

### Table 3 Cord blood cytokine concentrations (Continued)

|               | LLD | median       | IQR       |
|---------------|-----|--------------|-----------|
| IL-1α         | 6.664 | 6.66 (6.66,13.9) | 6.66 (6.66,13.1) |
| IL-1β         | 7.806 | 7.81 (7.81,60.1) | 7.81 (7.81,47.4) |
| IL-2          | 2.538 | 33.7 (2.58,17) | 33.7 (21.8,69.2) |
| IL-4          | 0.776 | 0.776 (0.785,2) | 0.776 (0.784,5) |
| IL-5          | 35.05 | 35.1 (35.11,14) | 35.1 (35.11,24) |
| IL-6          | 18.466 | 20.1 (18.5,65.1) | 20.1 (18.5,40.7) |
| IL-8          | 9.894 | 35.7 (9.89,83) | 9.895 (9.89,55.9) |
| IL-10         | 2.94 | 2.94 (2.94,17) | 2.94 (2.94,36.3) |
| IL-12p70      | 45.458 | 45.5 (45.51,98) | 45.5 (45.51,50) |
| IL-13         | 12.608 | 12.6 (12.6,67.3) | 12.6 (12.6,36.3) |
| IL-15         | 7.734 | 7.73 (7.73,73) | 7.73 (7.73,73) |
| IL-17         | 45.586 | 45.6 (45.6,26.2) | 45.6 (45.6,46.5) |
| IFNγ          | 58.506 | 58.5 (58.5188) | 58.5 (58.5193) |
| MCP-1         | 5.686 | 309 (192,509) | 309 (188,473) |
| TNFα          | 15.146 | 15.1 (15.1,101) | 15.1 (15.1,101) |
Unit). This project was also supported in part by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number 8UL1TR000041, The University of New Mexico Clinical and Translational Science Center.

The Nordic Naturals company, Watsonville, California, supplied the supplements and placebos described in this trial.

Availability of data and materials
The data analyzed in this manuscript are the property of the University of Michigan, Ann Arbor, and were made available to the University of New Mexico under a formal data sharing agreement; the data will not be publicly available. The plasma specimens described in this manuscript have been analyzed and destroyed, and as such will not be available for further analyses.

Authors’ contributions
ELM, AV, DV, and ZD designed the research. ELM, JC, CC, and VR conducted the research. CQ conducted the data analyses. EM, DB, ZD, AV, CQ and VR wrote the paper and had primary responsibility for the final content. All authors read and approved the final manuscript. No author had any relevant conflict of interest.

Ethics approval and consent to participate
The procedures followed were approved and conducted in accordance with the institutional review boards of the University of Michigan Medical Center, Ann Arbor, MI, study number HUM00004684; St. Joseph Mercy Hospital in Ypsilanti, MI, and The University of New Mexico Health Sciences Center Human Research Protections Office. All subjects gave written, informed consent to participate in the study. The trial was registered at clinicaltrials.gov: NCT00711971 under the title: consent to participate in the study. The trial was registered at clinicaltrials.gov: Human Research Protections Office. All subjects gave written, informed consent to participate. The procedures followed were approved and conducted in accordance with the institutional review boards of the University of Michigan Medical Center, Ann Arbor, MI, study number HUM00004684; St. Joseph Mercy Hospital in Ypsilanti, MI, and The University of New Mexico Health Sciences Center Human Research Protections Office. All subjects gave written, informed consent to participate in the study. The trial was registered at clinicaltrials.gov: NCT00711971 under the title: “Does Fish Oil Prevent Depression in Pregnancy and Postpartum.”

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, MSC 10 5580, 1 University of New Mexico, Albuquerque, NM 87131, USA. 2 Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA. 3 Obstetrics and Gynecology, Duke University, Durham, NC, USA. 4 Obstetrics and Gynecology, Spectrum Health Maternal Fetal Medicine, Grand Rapids, MI/Michigan State University College of Human Medicine, East Lansing, MI, USA. 5 Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA. 6 Clinical and Translational Center, University of New Mexico, Albuquerque, NM, USA. 7 Family Medicine, University of Michigan, Ann Arbor, MI, USA.

Received: 4 December 2017 Accepted: 14 June 2018
Published online: 26 June 2018

References
1. Osborne LM, Monk C. Perinatal depression—The fourth inflammatory morbidity of pregnancy? Psychoneuroendocrinology. 2013;38:1929–52.
2. Lekva Tove T. Impact of Systemic Inflammation on the Progression of Gestational Diabetes Mellitus. Curr Diabet Rep. 2016;16:26.
3. Ferguson KK, Meeker JD, McElrath TF, Mukherjee B, Cantonwine DE. Repeated measures of inflammation and oxidative stress biomarkers in preeclampsia and normotensive pregnancies. Am J Obstet Gynecol. 2017;216(1):527.
4. Chang JP, Lin C, Lin P, Shih Y, Chiu H, Ho M, et al. Polyunsaturated fatty acids and inflammatory markers in major depressive episodes during pregnancy. Prog Neuropsychopharmacol Biol Psychiatry. 2018;80Pt C:273–8.
5. Manzel A, Muller DN, Hafler DA, Erdman SE, Linker RA, Kleinnewiersfeld M. Role of “Western diet” in inflammatory autoimmune diseases. Curr Allergy Asthma Rep. 2014;14:404.
6. Thorburn AN, Macia L, Mackay CR. Diet, metabolites, and “western-lifestyle” inflammatory diseases. Immunity. 2014;40:833–42.
7. Zarate CA, B Iaboni-Vazdeki N, Tejera N, Pérez JA, Rodríguez C. Significance of long chain polyunsaturated fatty acids in human health. Clin Trans Med. 2017;6:25.
8. Meydani SN, Endres S, Woods MM, Goldin BR, Soco C, Mollir-Labrodie A, et al. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: Comparison between young and older women. J Nutr. 1991;121:547–55.
9. Caughey G, Mantlois E, Gibson R, Cledan L, James M. The effect on human tumor necrosis factor alpha and interleukin 1beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr. 1996;63:116–22.
10. Rangel-Huerta OD, Aguilera CM, Mesa MD, Gil A. Omega-3 long-chain polyunsaturated fatty acids supplementation of inflammatory biomarkers: A systematic review of randomized clinical trials. Br J Nutr. 2012;107(Suppl 2):S159–70. https://doi.org/10.1017/S0007114512001559.
11. Pot GK, Brouwer IA, Ennenman A, Rijkers GT, Kampman E, Geelen A. No effect of fish oil supplementation on serum inflammatory markers and their interrelationships: A randomized controlled trial in healthy, middle-aged individuals. Eur J Clin Nutr. 2009;63:1353–9. https://doi.org/10.1038/ejcn.2009663.
12. Mozurkewich E, Chilimigias J, Klemens C, Keeton K, Allbaugh L, Hamilton S, et al. The mothers, omega-3 and mental health study. BMC Pregnancy Childbirth. 2011;11:46.
13. Mozurkewich E, Clinton CM, Chilimigias JL, Hamilton SE, Allbaugh L, Berman DR, et al. The mothers, omega-3, and mental health study: A double-blind, randomized controlled trial. Am J Obstet Gynecol. 2013;208:313.e1,313.e9.
14. Plei JD. Imputing defensible values for left-censored ‘below level of quantitation’ (LOQ) biomarker measurements. J Breath Research. 2016;10:045001.
15. Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y. The paradoxical role of IL-10 in immunity and cancer. Cancer Lett. 2015;367:103–7.
16. Young Juan Joseph JJ. A review of the relationship between proinflammatory cytokines and major depressive disorder. J Affect Disord. 2014;169:15–20.
17. Haghiac M, Yang XH, Presley L, Smith S, Dettelback S, Minium J, at al: Dietary Omega-3 Fatty Acid Supplementation Reduces Inflammation in Obese Pregnant Women: A Randomized Double-Blind Controlled Clinical Trial. PLoS One. 2015;10:e0137309.
18. Morin C, Charbonneau L, Ouellet N, Ouellet H, Blier P, Dufresne F, et al. Eicosapentaenoic acid monoglyceride resolves inflammation in an ex vivo model of human peripheral blood mononuclear cell. Eur J Pharmacol. 2017;807:205–11.
19. Klemens CM, Berman DR, Mozurkewich EL. The effect of perinatal omega-3 fatty acid supplementation on inflammatory markers and allergic diseases: a systematic review. BJOG. 2011;118:916–25.
20. Romero VC, Somers EC, Stolberg V, Clinton C, Chenhue S, Djuric Z, et al. Developmental programming for allergy: A secondary analysis of the Mothers, Omega-3, and Mental Health Study. Am J Obstet Gynecol. 2013;208:1–6.